Atyr_Logo.png
aTyr Pharma to Present at BIO CEO & Investor Conference
February 07, 2022 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
 aTyr Pharma Advances Development of Lead Therapeutic Candidate ATYR1923 with Announcement of “efzofitimod” as Nonproprietary Name
January 13, 2022 08:03 ET | aTyr Pharma, Inc.
SAN DIEGO, Jan. 13, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces FDA Orphan Drug Designation for ATYR1923 for Treatment of Sarcoidosis
January 06, 2022 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
Atyr_Logo.png
aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources
December 24, 2021 08:02 ET | aTyr Pharma, Inc.
SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference
December 10, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Dec. 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
November 30, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma to Present at Upcoming Investor Conferences in November
November 12, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update
November 10, 2021 16:00 ET | aTyr Pharma, Inc.
Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2...
Atyr_Logo.png
aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
November 09, 2021 08:05 ET | aTyr Pharma, Inc.
 Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data...
Atyr_Logo.png
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
November 03, 2021 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...